An update on the pathobiological relevance of nuclear receptors for cancers of the head and neck

Histology and Histopathology

Volumn 25, Issue 8, 2010, Pages 1093-1104

  Stauber, Roland H ^a   Wünsch, Desiree ^a   Knauer, Shirley K ^b   Fetz, Verena ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

Chemoprevention; Chemotherapy; Hormone response element; PPAR; RAR; Retinoids; RXR; Squamous cell carcinoma; Tamoxifen; Transcriptional activation

Indexed keywords

CELL RECEPTOR; RETINOID; THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; HEAD AND NECK TUMOR; HUMAN; NEOPLASM; PHYSIOLOGY; REVIEW; SURVIVAL RATE;

CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, THYROID HORMONE; RETINOIDS; SURVIVAL RATE; TRANSCRIPTION FACTORS;

EID: 77956932798     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Altucci L., Leibowitz M. D., Ogilvie K. M., de Lera A. R. and Gronemeyer H. (2007). RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 6, 793-810.
2. Argiris A., Karamouzis M. V., Raben D. and Ferris R. L. (2008). Head and neck cancer. Lancet 371, 1695-1709.
3. Baetz T., Eisenhauer E., Siu L., MacLean M., Doppler K., Walsh W., Fisher B., Khan A. Z., de Alwis D. P., Weitzman A., Brail L. H. and Moore M. (2007). A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Invest. New Drugs 25, 217-225.
4. Bernier J. (2008). A multidisciplinary approach to squamous cell carcinomas of the head and neck: an update. Curr. Opin. Oncol. 20, 249-255.
5. Biggins J. B. and Koh J. T. (2007). Chemical biology of steroid and nuclear hormone receptors. Curr. Opin. Chem. Biol. 11, 99-110.
6. Bonner J. A., Harari P. M., Giralt J., Azarnia N., Shin D. M., Cohen R. B., Jones C. U., Sur R., Raben D., Jassem J., Ove R., Kies M. S., Baselga J., Youssoufian H., Amellal N., Rowinsky E. K. and Ang K. K. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578.
7. Campbell M. J. and Adorini L. (2006). The vitamin D receptor as a therapeutic target. Expert. Opin. Ther. Targets 10, 735-748.
8. Dahlman-Wright K., Cavailles V., Fuqua S. A., Jordan V. C., Katzenellenbogen J. A., Korach K. S., Maggi A., Muramatsu M., Parker M. G. and Gustafsson J. A. (2006). International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol. Rev. 58, 773-781.
9. de Lera A. R., Bourguet W., Altucci L. and Gronemeyer H. (2007). Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat. Rev. Drug Discov. 6, 811-820.
10. Dragnev K. H., Pitha-Rowe I., Ma Y., Petty W. J., Sekula D., Murphy B., Rendi M., Suh N., Desai N. B., Sporn M. B., Freemantle S. J. and Dmitrovsky E. (2004). Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin. Cancer Res. 10, 2570-2577.
11. Eibl G. (2008). The Role of PPAR-gamma and Its Interaction with COX-2 in Pancreatic Cancer. PPAR Res. 2008, 326915.
12. Fakhry C., Westra W. H., Li S., Cmelak A., Ridge J. A., Pinto H., Forastiere A. and Gillison M. L. (2008). Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst. 100, 261-269.
13. Forastiere A., Weber R. and Ang K. (2008). Treatment of head and neck cancer. N. Engl. J. Med. 358, 1076; author reply 1077-1078.
14. Forastiere A. A. (2008). Chemotherapy in the treatment of locally advanced head and neck cancer. J. Surg. Oncol. 97, 701-707.
15. Forastiere A. A., Trotti A., Pfister D. G. and Grandis J. R. (2006). Head and neck cancer: recent advances and new standards of care. J. Clin. Oncol. 24, 2603-2605.
16. Freemantle S. J., Dragnev K. H. and Dmitrovsky E. (2006). The retinoic acid paradox in cancer chemoprevention. J. Natl. Cancer Inst. 98, 426-427.
17. Germain P., Staels B., Dacquet C., Spedding M. and Laudet V. (2006). Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58, 685-704.
18. Gollamudi R., Gupta D., Goel S. and Mani S. (2008). Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism. Curr. Drug Metab. 9, 611-613.
19. Gronemeyer H., Gustafsson J. A. and Laudet V. (2004). Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3, 950-964. (Pubitemid 39534319)
20. Hager G., Formanek M., Gedlicka C., Thurnher D., Knerer B. and Kornfehl J. (2001). 1, 25 (OH) 2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol. 121, 103-109.
21. Hamakawa H., Nakashiro K., Sumida T., Shintani S., Myers J. N., Takes R. P., Rinaldo A. and Ferlito A. (2008). Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 30, 800-809.
22. Higuchi E., Chandraratna R. A., Hong W. K. and Lotan R. (2003). Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype. Oncogene 22, 4627-4635.
23. Hsu P. P. and Sabatini D. M. (2008). Cancer cell metabolism: Warburg and beyond. Cell 134, 703-707.
24. Hsueh W. A. and Bruemmer D. (2004). Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 43, 297-305.
25. Ishida H., Wada K., Masuda T., Okura M., Kohama K., Sano Y., Nakajima A., Kogo M. and Kamisaki Y. (2007). Critical role of estrogen receptor on anoikis and invasion of squamous cell carcinoma. Cancer Sci. 98, 636-643.
26. Jemal A., Siegel R., Ward E., Hao Y., Xu J. and Thun M. J. (2009). Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249.
27. Kalayarasan R., Ananthakrishnan N., Kate V. and Basu D. (2008). Estrogen and progesterone receptors in esophageal carcinoma. Dis. Esophagus 21, 298-303.
28. Kebebew E., Peng M., Reiff E., Treseler P., Woeber K. A., Clark O. H., Greenspan F. S., Lindsay S., Duh Q. Y. and Morita E. (2006). A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 140, 960-966; discussion 966-967.
29. Khuri F. R., Lippman S. M., Spitz M. R., Lotan R. and Hong W. K. (1997). Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J. Natl. Cancer Inst. 89, 199-211.
30. Khuri F. R., Lee J. J., Lippman S. M., Kim E. S., Cooper J. S., Benner S. E., Winn R., Pajak T. F., Williams B., Shenouda G., Hodson I., Fu K., Shin D. M., Vokes E. E., Feng L., Goepfert H. and Hong W. K. (2006). Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J. Natl. Cancer Inst. 98, 441-450.
31. Kim E. H. and Surh Y. J. (2008). The role of 15-deoxy-delta (12, 14) - prostaglandin J (2), an endogenous ligand of peroxisome proliferatoractivated receptor gamma, in tumor angiogenesis. Biochem. Pharmacol. 76, 1544-1553.
32. Kramer O. H., Knauer S. K., Zimmermann D., Stauber R. H. and Heinzel T. (2008). Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 27, 732-740.
33. Kroemer G. and Pouyssegur J. (2008). Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482.
34. Ku T. K. and Crowe D. L. (2007). Coactivator-mediated estrogen response in human squamous cell carcinoma lines. J. Endocrinol. 193, 147-155.
35. Lehrke M. and Lazar M. A. (2005). The many faces of PPARgamma. Cell 123, 993-999.
36. Lin R., Wang T. T., Miller W. H. Jr and White J. H. (2003). Inhibition of F-Box protein p45 (SKP2) expression and stabilization of cyclindependent kinase inhibitor p27 (KIP1) in vitamin D analog-treated cancer cells. Endocrinology 144, 749-753.
37. Lippert B. M., Knauer S. K., Fetz V., Mann W. and Stauber R. H. (2007). Dynamic survivin in head and neck cancer: molecular mechanism and therapeutic potential. Int. J. Cancer 121, 1169-1174.
38. Liu Z., Calderon J. I., Zhang Z., Sturgis E. M., Spitz M. R. and Wei Q. (2005). Polymorphisms of vitamin D receptor gene protect against the risk of head and neck cancer. Pharmacogenet. Genomics 15, 159-165.
39. Lu L., Qiu J., Liu S. and Luo W. (2008). Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57. Mol. Cancer Ther. 7, 1268-1274.
40. Lu N. Z., Wardell S. E., Burnstein K. L., Defranco D., Fuller P. J., Giguere V., Hochberg R. B., McKay L., Renoir J. M., Weigel N. L., Wilson E. M., McDonnell D. P. and Cidlowski J. A. (2006). International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol. Rev. 58, 782-797.
41. Lukits J., Remenar E., Raso E., Ladanyi A., Kasler M. and Timar J. (2007). Molecular identification, expression and prognostic role of estrogen-and progesterone receptors in head and neck cancer. Int. J. Oncol. 30, 155-160.
42. Mao L., Hong W. K. and Papadimitrakopoulou V. A. (2004). Focus on head and neck cancer. Cancer Cell 5, 311-316.
43. Martinez I., Wang J., Hobson K. F., Ferris R. L. and Khan S. A. (2007). Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur. J. Cancer 43, 415-432.
44. Masuda T., Wada K., Nakajima A., Okura M., Kudo C., Kadowaki T., Kogo M. and Kamisaki Y. (2005). Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma. Clin. Cancer Res. 11, 4012-4021.
45. Michalik L. and Wahli W. (2007). Guiding ligands to nuclear receptors. Cell 129, 649-651.
46. Michalik L. and Wahli W. (2008). PPARs mediate lipid signaling in inflammation and cancer. PPAR Res. 2008, 134059.
47. Nagpal S., Na S. and Rathnachalam R. (2005). Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev. 26, 662-687.
48. Nettles K. W. and Greene G. L. (2005). Ligand control of coregulator recruitment to nuclear receptors. Annu. Rev. Physiol. 67, 309-333.
49. Nozoe T., Oyama T., Takenoyama M., Hanagiri T., Sugio K. and Yasumoto K. (2007). Significance of immunohistochemical expression of estrogen receptors alpha and beta in squamous cell carcinoma of the esophagus. Clin. Cancer Res. 13, 4046-4050. (Pubitemid 47105964)
50. Osborne C. K. and Schiff R. (2005). Estrogen-receptor biology: continuing progress and therapeutic implications. J. Clin. Oncol. 23, 1616-1622.
51. Perissi V. and Rosenfeld M. G. (2005). Controlling nuclear receptors: the circular logic of cofactor cycles. Nat. Rev. Mol. Cell Biol. 6, 542-554.
52. Petty W. J., Li N., Biddle A., Bounds R., Nitkin C., Ma Y., Dragnev K. H., Freemantle S. J. and Dmitrovsky E. (2005). A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J. Natl. Cancer Inst. 97, 1645-1651.
53. Raimondi S., Johansson H., Maisonneuve P. and Gandini S. (2009). Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 30, 1170-1180.
54. Ralhan R., Chakravarti N., Kaur J., Sharma C., Kumar A., Mathur M., Bahadur S., Shukla N. K. and Deo S. V. (2006). Clinical significance of altered expression of retinoid receptors in oral precancerous and cancerous lesions: relationship with cell cycle regulators. Int. J. Cancer 118, 1077-1089.
55. Rapidis A. D., Vermorken J. B. and Bourhis J. (2008). Targeted therapies in head and neck cancer: past, present and future. Rev. Recent Clin. Trials 3, 156-166.
56. Schug T. T., Berry D. C., Shaw N. S., Travis S. N. and Noy N. (2007). Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129, 723-733.
57. Schweitzer A., Knauer S. K. and Stauber R. H. (2008). Therapeutic potential of nuclear receptors. Expert Opinion on Therapeutic Patents 18, 861-888.
58. Shulman A. I. and Mangelsdorf D. J. (2005). Retinoid x receptor heterodimers in the metabolic syndrome. N. Engl. J. Med. 353, 604-615.
59. Slattery M. L. (2007). Vitamin D receptor gene (VDR) associations with cancer. Nutr. Rev. 65, S102-104.
60. Specenier P. M. and Vermorken J. B. (2009). Current concepts for the management of head and neck cancer: chemotherapy. Oral Oncol. 45, 409-415.
61. Takahashi T. and Morikawa K. (2006). Vitamin D receptor agonists: opportunities and challenges in drug discovery. Curr. Top. Med. Chem. 6, 1303-1316.
62. Thorne J. and Campbell M. J. (2008). The vitamin D receptor in cancer. Proc. Nutr. Soc. 67, 115-127.
63. Uma R. S., Naresh K. N., D'Cruz A. K., Mulherkar R. and Borges A. M. (2007). Metastasis of squamous cell carcinoma of the oral tongue is associated with down-regulation of epidermal fatty acid binding protein (E-FABP). Oral Oncol. 43, 27-32.
64. Vattemi E., Graiff C., Sava T., Pedersini R., Caldara A. and Mandara M. (2008). Systemic therapies for recurrent and/or metastatic salivary gland cancers. Expert Rev. Anticancer Ther. 8, 393-402.
65. Vogelstein B. and Kinzler K. W. (2004). Cancer genes and the pathways they control. Nat. Med. 10, 789-799.
66. Wang N. (2008). PPAR-delta in vascular pathophysiology. PPAR Res. 164163.
67. Whiteside T. L. (2008). The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904-5912.
68. Wrangle J. M. and Khuri F. R. (2007). Chemoprevention of squamous cell carcinoma of the head and neck. Curr. Opin. Oncol. 19, 180-187.
69. Wu X., Zhao H., Do K. A., Johnson M. M., Dong Q., Hong W. K. and Spitz M. R. (2004). Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin. Cancer Res. 10, 3988-3995.
70. Yasui Y., Kim M. and Tanaka T. (2008). PPAR ligands for cancer chemoprevention. PPAR Res. 2008, 548919.
71. Youssef E. M., Lotan D., Issa J. P., Wakasa K., Fan Y. H., Mao L., Hassan K., Feng L., Lee J. J., Lippman S. M., Hong W. K. and Lotan R. (2004). Hypermethylation of the retinoic acid receptor-beta (2) gene in head and neck carcinogenesis. Clin. Cancer Res. 10, 1733-1742.